CN103096933A - 多功能抗体缀合物 - Google Patents

多功能抗体缀合物 Download PDF

Info

Publication number
CN103096933A
CN103096933A CN2011800438472A CN201180043847A CN103096933A CN 103096933 A CN103096933 A CN 103096933A CN 2011800438472 A CN2011800438472 A CN 2011800438472A CN 201180043847 A CN201180043847 A CN 201180043847A CN 103096933 A CN103096933 A CN 103096933A
Authority
CN
China
Prior art keywords
mac
antibody
seq
peptide
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800438472A
Other languages
English (en)
Chinese (zh)
Inventor
A·S·巴特
C·W·布拉德肖
O·A·劳伦特
R·R·普雷斯顿
D·图梅尔蒂
L·D·伍德
W·H·于
A·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ireland Kaufkes Technology Co ltd
Covx Technologies Ireland Ltd
Original Assignee
Ireland Kaufkes Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ireland Kaufkes Technology Co ltd filed Critical Ireland Kaufkes Technology Co ltd
Publication of CN103096933A publication Critical patent/CN103096933A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN2011800438472A 2010-07-12 2011-07-11 多功能抗体缀合物 Pending CN103096933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36350710P 2010-07-12 2010-07-12
US61/363,507 2010-07-12
PCT/IB2011/053092 WO2012007896A1 (en) 2010-07-12 2011-07-11 Multifunctional antibody conjugates

Publications (1)

Publication Number Publication Date
CN103096933A true CN103096933A (zh) 2013-05-08

Family

ID=44630490

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800438472A Pending CN103096933A (zh) 2010-07-12 2011-07-11 多功能抗体缀合物

Country Status (19)

Country Link
US (1) US8741291B2 (OSRAM)
EP (1) EP2593142B8 (OSRAM)
JP (2) JP5913307B2 (OSRAM)
KR (1) KR20130050966A (OSRAM)
CN (1) CN103096933A (OSRAM)
AR (1) AR082205A1 (OSRAM)
AU (1) AU2011277999A1 (OSRAM)
BR (1) BR112013000951A2 (OSRAM)
CA (1) CA2804185C (OSRAM)
CO (1) CO6670522A2 (OSRAM)
ES (1) ES2704223T3 (OSRAM)
MX (1) MX2013000491A (OSRAM)
PE (1) PE20130643A1 (OSRAM)
PH (1) PH12013500070A1 (OSRAM)
RU (1) RU2012157167A (OSRAM)
SG (1) SG186451A1 (OSRAM)
TW (1) TWI432213B (OSRAM)
WO (1) WO2012007896A1 (OSRAM)
ZA (1) ZA201300161B (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949575A (zh) * 2015-06-19 2018-04-20 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN108883170A (zh) * 2015-10-23 2018-11-23 索伦托治疗有限公司 可程序化的通用细胞受体及其使用方法
CN118805740A (zh) * 2024-08-07 2024-10-22 中国中医科学院中药研究所 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20140260A1 (es) * 2010-11-05 2014-03-19 Pfizer Compuestos antidiabeticos
BR112013032928A2 (pt) * 2011-06-21 2017-01-24 Immunogen Inc "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos"
WO2013072813A2 (en) 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
EP3447071A1 (en) 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Mutant antibodies and conjugation thereof
KR102237639B1 (ko) 2012-10-11 2021-04-07 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트
ES2782248T3 (es) 2012-10-19 2020-09-11 Daiichi Sankyo Co Ltd Conjugado de anticuerpo y fármaco producido por la unión a través de un enlazador que tiene estructura hidrófila
AU2013343111A1 (en) 2012-11-07 2015-05-14 Pfizer Inc. Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates
MX2015005810A (es) 2012-11-07 2015-09-23 Pfizer Anticuerpos anti-notch y conjugados de anticuerpo-farmaco.
RU2670943C9 (ru) 2012-11-08 2018-11-26 Илэвэн Байотерапьютикс, Инк. Антагонисты ил-6 и их применение
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
WO2015057066A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
WO2015057063A1 (en) * 2013-10-14 2015-04-23 Synaffix B.V. Modified glycoprotein, protein-conjugate and process for the preparation thereof
IL320281A (en) 2013-12-25 2025-06-01 Daiichi Sankyo Co Ltd Anti-trop2 antibodies and methods for producing same
PH12020552271A1 (en) 2014-01-31 2022-05-02 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
DK3129063T3 (da) 2014-04-10 2021-04-06 Daiichi Sankyo Co Ltd Anti-her3-antistof-lægemiddelkonjugat
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
MY185114A (en) 2014-11-07 2021-04-30 Sesen Bio Inc Improved il-6 antibodies
CN107847588B (zh) * 2015-05-20 2021-12-28 免疫功坊股份有限公司 具有靶向部分及效应部分的分子构建体及其应用
US11173213B2 (en) 2015-06-29 2021-11-16 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CA2996652A1 (en) * 2015-09-01 2017-03-09 Immunwork Inc. Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
JP6990650B2 (ja) * 2015-09-17 2022-03-04 ザ スクリプス リサーチ インスティテュート 二重可変ドメインイムノコンジュゲートおよびその用途
US20220008553A1 (en) * 2015-11-23 2022-01-13 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
JP2019518017A (ja) 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
CN108718522A (zh) * 2016-02-23 2018-10-30 赛森生物股份有限公司 Il-6拮抗剂制剂及其用途
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
CN110049779A (zh) 2016-12-12 2019-07-23 第一三共株式会社 抗体-药物缀合物和免疫检查点抑制剂的组合
EP3572428A4 (en) 2017-01-17 2020-12-30 Daiichi Sankyo Company, Limited ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20
KR20190111086A (ko) 2017-01-24 2019-10-01 화이자 인코포레이티드 칼리키아마이신 유도체 및 이의 항체 약물 접합체
TW202530271A (zh) 2017-05-15 2025-08-01 日商第一三共股份有限公司 抗體－藥物結合物及其用途
KR20250084239A (ko) 2017-08-31 2025-06-10 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 개량 제조 방법
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
WO2019090242A1 (en) * 2017-11-04 2019-05-09 Advanced Proteome Therapeutics Inc. Composition and method for modifying polypeptides
EP3737699A1 (en) 2018-01-12 2020-11-18 Amgen Inc. Pac1 antibodies and uses thereof
US12479926B2 (en) 2018-05-18 2025-11-25 Daiichi Sankyo Co., Ltd. Anti-MUC1 antibody-drug conjugate
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
US12220604B2 (en) 2018-07-31 2025-02-11 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of an antibody-drug conjugate
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
SG11202100934PA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
KR20210081324A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN113330029A (zh) * 2019-08-19 2021-08-31 沈阳药科大学 抗体的突变体及其应用
US20220347312A1 (en) 2019-09-04 2022-11-03 Bolt Biotherapeutics, Inc. Immunoconjugate Synthesis Method
AU2022309028A1 (en) 2021-07-09 2024-01-25 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
EP4370157A1 (en) 2021-07-14 2024-05-22 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates
MX2024005332A (es) * 2021-11-01 2024-05-20 Dyne Therapeutics Inc Complejos dirigidos al musculo para el tratamiento de distrofinopatias.
EP4508091A1 (en) * 2022-04-15 2025-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
AU2023350248A1 (en) 2022-09-30 2025-04-17 Shanghai De Novo Pharmatech Co., Ltd. Benzazepine derivative, conjugate containing same, and use thereof
AU2024229817A1 (en) 2023-02-28 2025-08-14 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Chemical coupling linker and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115165A1 (en) * 2002-11-25 2004-06-17 Perry Rosen Bifunctional polyethylene glycol derivatives
US20080166364A1 (en) * 2006-11-10 2008-07-10 Curt Bradshaw Anti-angiogenic compounds
WO2009136352A1 (en) * 2008-05-05 2009-11-12 Covx Technologies Ireland, Ltd. Anti-angiogenic compounds

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
EP1228087B1 (en) 1999-10-08 2010-06-09 The Scripps Research Institute Antibody catalysis of enantio- and diastereo-selective aldol reactions
MA26040A1 (fr) 2001-01-05 2004-04-01 Pfizer Des anticorps pour recepteur i de facteur de croissance insulinique
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
JP4638870B2 (ja) 2003-08-13 2011-02-23 ファイザー・プロダクツ・インク 修飾ヒトｉｇｆ−１ｒ抗体
CA2598833A1 (en) 2005-03-03 2006-09-08 Curt W. Bradshaw Anti-angiogenic compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
EP2190480A4 (en) 2007-08-28 2013-01-23 Biogen Idec Inc ANTI-IGR-1R ANTIBODIES AND ITS USES
CN115043946A (zh) 2008-01-03 2022-09-13 斯克里普斯研究院 通过模块识别结构域的抗体靶向
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115165A1 (en) * 2002-11-25 2004-06-17 Perry Rosen Bifunctional polyethylene glycol derivatives
US20080166364A1 (en) * 2006-11-10 2008-07-10 Curt Bradshaw Anti-angiogenic compounds
WO2009136352A1 (en) * 2008-05-05 2009-11-12 Covx Technologies Ireland, Ltd. Anti-angiogenic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LINTAO WANG, ET AL: "Structural characterization of the maytansinoid–monoclonal antibody immunoconjugate,huN901–DM1, by mass spectrometry", 《PROTEIN SCIENCE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107949575A (zh) * 2015-06-19 2018-04-20 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN107949575B (zh) * 2015-06-19 2022-03-08 卫材R&D管理有限公司 Cys80缀合型免疫球蛋白
CN108883170A (zh) * 2015-10-23 2018-11-23 索伦托治疗有限公司 可程序化的通用细胞受体及其使用方法
CN118805740A (zh) * 2024-08-07 2024-10-22 中国中医科学院中药研究所 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用

Also Published As

Publication number Publication date
KR20130050966A (ko) 2013-05-16
JP5913307B2 (ja) 2016-04-27
CO6670522A2 (es) 2013-05-15
CA2804185A1 (en) 2012-01-19
AR082205A1 (es) 2012-11-21
PE20130643A1 (es) 2013-06-07
ES2704223T3 (es) 2019-03-15
TW201216986A (en) 2012-05-01
EP2593142B1 (en) 2018-10-10
AU2011277999A1 (en) 2013-01-10
JP6339995B2 (ja) 2018-06-06
ZA201300161B (en) 2013-09-25
CA2804185C (en) 2017-03-21
TWI432213B (zh) 2014-04-01
EP2593142B8 (en) 2018-12-26
EP2593142A1 (en) 2013-05-22
US20120201809A1 (en) 2012-08-09
RU2012157167A (ru) 2014-08-20
WO2012007896A1 (en) 2012-01-19
SG186451A1 (en) 2013-01-30
MX2013000491A (es) 2013-02-26
US8741291B2 (en) 2014-06-03
JP2016094455A (ja) 2016-05-26
BR112013000951A2 (pt) 2016-05-17
JP2013534535A (ja) 2013-09-05
PH12013500070A1 (en) 2017-08-23

Similar Documents

Publication Publication Date Title
JP6339995B2 (ja) 多機能性抗体複合体
CN108473591B (zh) 位点特异性her2抗体药物缀合物
JP7407841B2 (ja) クローディン１８ａ２に対する抗体及びその応用
US12441795B2 (en) Anti-ROR1 antibodies and preparation method and uses thereof
CN116617410A (zh) 用于癌症治疗的axl特异性抗体药物缀合物
AU2015271100A1 (en) Anti-HER2 antibody-maytansine conjugates and methods of use thereof
TW201617366A (zh) 新穎抗人類Ｔｉｅ２抗體
WO2019068758A1 (en) MODIFIED CYSTEINE MOLECULES BINDING TO ANTIGEN
TW202221034A (zh) 抗ｃｄ２２８抗體和抗體－藥物共軛體
HK1257352A1 (zh) 靶向gcc的抗体-药物缀合物
WO2024158047A1 (ja) 抗ｌｒｒｃ１５抗体
WO2021160138A1 (zh) 抗表皮生长因子受体的抗原结合蛋白及其应用
AU2023237240A1 (en) Anti-folate receptor alpha antibodies and methods of use
US20250195679A1 (en) Antibody-drug conjugate and use thereof
TW202237135A (zh) 抗體-吡咯并苯并二氮呯衍生物結合物
HK1188384A (en) Multifunctional antibody conjugates
TW202442681A (zh) 抗ror1抗體及其藥物偶聯物
WO2025184730A1 (en) Antibody constructs binding folate receptor alpha and napi2b, conjugates and methods of use
CN118791622A (zh) 抗ror1抗体及其药物偶联物
WO2025237392A1 (zh) 新型抗egfr抗体、药物偶联物及其用途
CN118165107A (zh) 结合tigit的抗体分子
HK1258498B (en) Site specific her2 antibody drug conjugates
HK1258498A1 (en) Site specific her2 antibody drug conjugates

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1188384

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130508

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1188384

Country of ref document: HK